ERBB2 and cancer: While the herceptin-derived anti-ErbB2 CAR produced serious side effects, so far hampering its further clinical exploration [3], the targeting selectivity of the fusion protein redirected the CAR T cells towards the cancer cells versus the healthy fibroblasts with the physiological ErbB2 levels, was unexpectedly high.